Geneva, March 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119425) titled 'Adebrelimab plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer: A Single-Arm, Exploratory Study' on Feb. 27.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Tangdu Hospital, Air Force Military Medical University

Condition: bladder cancer

Recruitment Status: Recruiting

Phase: 2

Date of First Enrollment: 2026-02-27

Target Sample Size: Experimental group:32;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=309352

Published by HT Digital Content Services with permission from Health Daily Dig...